Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H0T7

UPID:
RAB17_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H0T7; Q53QV6; Q6IA73; Q6PJZ0; Q9BVU1; Q9H9U9

BACKGROUND:
The Ras-related protein Rab-17 is a key regulator of the dynamic process of intracellular membrane trafficking. It is essential for the directed movement of endocytosed material across the cell, playing a significant role in transcytosis. This protein's function is vital for the transport and release of melanosomes from melanocytes and is implicated in the development of dendrites and dendritic spines, indicating its importance in cellular structure and migration.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Ras-related protein Rab-17 could open doors to potential therapeutic strategies. Given its critical role in membrane trafficking and cellular transport, targeting Rab-17 could lead to innovative treatments for disorders associated with these processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.